SHANGHAI FUDAN-ZHANGJIANG BIO-PHARMACEUTICAL CO.,LTD. Financials Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.
Equities
1349
CNE1000000W4
Pharmaceuticals
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.17 HKD | +2.36% |
|
+4.33% | -14.90% |
| Apr. 22 | Shanghai Fudan-Zhangjiang Buys Structured Deposits Worth 200 Million Yuan | MT |
| Apr. 01 | Fudan-Zhangjiang Bio Sees Profit, Revenue Drop in 2023 | MT |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 3,169 | 3,679 | 13,240 | 10,946 | 6,860 | 7,323 |
| Enterprise Value (EV) 1 | 2,728 | 3,257 | 11,862 | 9,769 | 5,695 | 6,144 |
| P/E ratio | 21 x | 16.2 x | 19.3 x | 15.7 x | 23.6 x | 22.1 x |
| Yield | 2.04% | 1.76% | 1.56% | 2.23% | 2.28% | 3.02% |
| Capitalization / Revenue | 4.28 x | 3.57 x | 15.9 x | 9.6 x | 6.65 x | 8.61 x |
| EV / Revenue | 3.68 x | 3.16 x | 14.2 x | 8.57 x | 5.52 x | 7.22 x |
| EV / EBITDA | 14.5 x | 11.2 x | 63.7 x | 46.7 x | 35.3 x | 50 x |
| EV / FCF | 22.7 x | 20.6 x | 356 x | 84.2 x | 100 x | 330 x |
| FCF Yield | 4.4% | 4.84% | 0.28% | 1.19% | 1% | 0.3% |
| Price to Book | 3.23 x | 3.95 x | 1.66 x | 1.48 x | 1.4 x | 1.02 x |
| Nbr of stocks (in thousands) | 923,000 | 923,000 | 1,043,000 | 1,032,135 | 1,029,000 | 1,036,572 |
| Reference price 2 | 3.433 | 3.986 | 3.207 | 3.137 | 3.065 | 2.318 |
| Announcement Date | 4/3/19 | 3/4/20 | 3/25/21 | 3/28/22 | 3/27/23 | 3/28/24 |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 740.4 | 1,029 | 833.8 | 1,140 | 1,031 | 850.7 |
| EBITDA 1 | 188.1 | 290.7 | 186.1 | 209.1 | 161.4 | 122.8 |
| EBIT 1 | 135.6 | 245 | 142.7 | 162.7 | 114.1 | 77.15 |
| Operating Margin | 18.32% | 23.81% | 17.12% | 14.27% | 11.06% | 9.07% |
| Earnings before Tax (EBT) 1 | 143.1 | 246.3 | 176.7 | 215.9 | 132.3 | 97.53 |
| Net income 1 | 151 | 227.4 | 164.7 | 213.3 | 138 | 108.6 |
| Net margin | 20.39% | 22.09% | 19.75% | 18.71% | 13.38% | 12.77% |
| EPS 2 | 0.1636 | 0.2463 | 0.1664 | 0.2000 | 0.1300 | 0.1050 |
| Free Cash Flow 1 | 120 | 157.8 | 33.36 | 116 | 56.7 | 18.64 |
| FCF margin | 16.21% | 15.33% | 4% | 10.17% | 5.5% | 2.19% |
| FCF Conversion (EBITDA) | 63.82% | 54.28% | 17.92% | 55.49% | 35.12% | 15.18% |
| FCF Conversion (Net income) | 79.5% | 69.4% | 20.26% | 54.39% | 41.09% | 17.16% |
| Dividend per Share 2 | 0.0700 | 0.0700 | 0.0500 | 0.0700 | 0.0700 | 0.0700 |
| Announcement Date | 4/3/19 | 3/4/20 | 3/25/21 | 3/28/22 | 3/27/23 | 3/28/24 |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 441 | 422 | 1,377 | 1,178 | 1,164 | 1,179 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | 120 | 158 | 33.4 | 116 | 56.7 | 18.6 |
| ROE (net income / shareholders' equity) | 13.8% | 23.4% | 11.2% | 10.1% | 6.18% | 4.7% |
| ROA (Net income/ Total Assets) | 6.51% | 10.1% | 4.39% | 3.85% | 2.48% | 1.65% |
| Assets 1 | 2,319 | 2,252 | 3,752 | 5,539 | 5,571 | 6,592 |
| Book Value Per Share 2 | 1.060 | 1.010 | 1.930 | 2.120 | 2.190 | 2.270 |
| Cash Flow per Share 2 | 0.6400 | 0.6200 | 1.340 | 1.170 | 1.250 | 1.150 |
| Capex 1 | 37.7 | 40.4 | 42.4 | 120 | 87.3 | 99 |
| Capex / Sales | 5.09% | 3.92% | 5.09% | 10.53% | 8.47% | 11.63% |
| Announcement Date | 4/3/19 | 3/4/20 | 3/25/21 | 3/28/22 | 3/27/23 | 3/28/24 |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -14.90% | 818M | |
| +5.31% | 70.44B | |
| +10.97% | 8.94B | |
| -16.83% | 4.75B | |
| +43.48% | 4.5B | |
| +3.20% | 3.85B | |
| +18.82% | 2.38B | |
| -21.36% | 2.34B | |
| -29.67% | 2.2B | |
| +8.38% | 1.96B |
- Stock Market
- Equities
- 1349 Stock
- Financials Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.
